Stifel initiated coverage on Bicara Therapeutics with a new price target
$BCAX
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $47.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/23/2025 | $8.00 | Underweight → Equal Weight | Wells Fargo |
| 4/17/2025 | $8.00 | Underweight | Wells Fargo |
| 2/6/2025 | $31.00 | Outperform | Wedbush |
| 12/6/2024 | $42.00 | Buy | H.C. Wainwright |
| 11/5/2024 | $48.00 | Buy | Rodman & Renshaw |
| 10/8/2024 | Overweight | Cantor Fitzgerald | |
| 10/8/2024 | $35.00 | Overweight | Morgan Stanley |
| 10/8/2024 | Buy | TD Cowen |